Robert Wesolowski MD

Robert Wesolowski MD
Asst ProfessorCollege of Medicinewesolowski.12@osu.edu
Starling Loving Hall 320 W 10th Avenue Columbus Ohio 43210
Phone:614-366-8541Fax: 614-293-4372
  • Translational Therapeutics

Research Description

Dr. Wesolowski's research interests include breast cancer immunology, in particular myeloid-derived suppressor cells (MDSC) and early phase trials of experimental therapeutics. MDSC are important inhibitors of anti-tumor immune response. He studying using MDSC as biomarkers of response to neoadjuvant chemotherapy and recently received a grant supporting this work. He also coordinates phase I solid tumor trials for the Division of Oncology, serves as local principal investigator on several phase I trials and is a member of the Precision Medicine Clinic where cancer patients will have their tumor DNA sequenced to identify cancers with gene mutations that have commercially available drugs that target these gene mutations. Dr. Wesolowski provides clinical care to women with all stages of invasive breast cancer and sees phase I patients in the Precision Medicine Clinic.

Current Publications

  • Zhao M, Pan X, Layman R, Lustberg MB, Mrozek E, Macrae ER, Wesolowski R, Carothers S, Puhalla S, Shapiro CL, Ramaswamy BA Phase II study of bevacizumab in combination with trastuzumab and docetaxel in HER2 positive metastatic breast cancer.Invest New Drugs in press 6/5/2014
  • Lundberg JD, Crawford BS, Phillips G, Berger MJ, Wesolowski RIncidence of infusion-site reactions associated with peripheral intravenous administration of fosaprepitant.Support Care Cancer 22 1461-6 6/1/2014
  • Wesolowski R, Abdel-Rasoul M, Lustberg M, Paskell M, Shapiro CL, Macrae ERTreatment-related mortality with everolimus in cancer patients.Oncologist 19 661-8 6/1/2014
  • Arcopinto M, Cella CA, Wesolowski R, Salzano A, Bossone E, Cittadini A, Baliga RRPrimary prevention of cancer-related thrombosis: Special focus on ambulatory patients.Int J Cardiol 173 583-4 5/15/2014
  • Lustberg MB, Balasubramanian P, Miller B, Garcia-Villa A, Deighan C, Wu Y, Carothers S, Berger M, Ramaswamy B, Macrae ER, Wesolowski R, Layman RM, Mrozek E, Pan X, Summers TA, Shapiro CL, Chalmers JJHeterogeneous atypical cell populations are present in blood of metastatic breast cancer patients.Breast Cancer Res 16 R23 1/1/2014
  • Wenzell CM, Berger MJ, Blazer MA, Crawford BS, Griffith NL, Wesolowski R, Lustberg MB, Phillips GS, Ramaswamy B, Mrozek E, Flynn JM, Shapiro CL, Layman RMPilot study on the efficacy of an ondansetron- versus palonosetron-containing antiemetic regimen prior to highly emetogenic chemotherapy.Support Care Cancer 21 2845-51 10/1/2013
  • Poi MJ, Berger M, Lustberg M, Layman R, Shapiro CL, Ramaswamy B, Mrozek E, Olson E, Wesolowski RDocetaxel-induced skin toxicities in breast cancer patients subsequent to paclitaxel shortage: a case series and literature review.Support Care Cancer 21 2679-86 10/1/2013
  • Markowitz J, Wesolowski R, Papenfuss T, Brooks TR, Carson WEMyeloid-derived suppressor cells in breast cancer.Breast Cancer Res Treat 140 13-21 7/1/2013
  • Layman RM, Ruppert AS, Lynn M, Mrozek E, Ramaswamy B, Lustberg MB, Wesolowski R, Ottman S, Carothers S, Bingman A, Reinbolt R, Kraut EH, Shapiro CLSevere and prolonged lymphopenia observed in patients treated with bendamustine and erlotinib for metastatic triple negative breast cancer.Cancer Chemother Pharmacol 71 1183-90 5/1/2013

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu